QURE — uniQure N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1590560 ·
Netherlands
Last close
$42.63
Market Cap
$2.93B
52W High
$50.47
52W Low
$15.40
ADV30
2,610,480
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,562,000 | 3,343,000 | -44,269,000 | -53,535,000 | 778,706,000 | 139,994,000 | 629,363,000 |
| Dec 2025 | 5,568,000 | 5,133,000 | -51,494,000 | -37,086,000 | 824,908,000 | 80,240,000 | 626,007,000 |
| Sep 2025 | 3,701,000 | 3,303,000 | -49,489,000 | -80,529,000 | 888,382,000 | 597,056,000 | 659,636,000 |
| Jun 2025 | 5,262,000 | 4,606,000 | -42,885,000 | -37,719,000 | 584,890,000 | 253,778,000 | 588,893,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-172,106,000
Investing CF
$-243,158,000
Financing CF
$335,278,000
CapEx
$-645,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.74
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,382,471,000
Inventory
$0
Receivables
$3,562,000
ST Investments
$446,556,000
EBIT TTM
$-142,330,000
Pretax Income TTM
$-203,246,000
Interest Exp TTM
$60,916,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,093,000
EBITDA
$-174,856,992
Free Cash Flow
$-103,697,624
Enterprise Value
$2,764,347,648
Total Cash
$586,550,016
Total Debt
$545,656,000
Shares Out
68,754,298
Trailing EPS
$-3.49
Book Value
$2.37
ROE
-228.2%
ROA
-17.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 16,098,000 | -187,827,000 | -198,971,000 | 824,908,000 | 626,007,000 | — | -177,963,000 |
| Dec 2024 | 27,119,000 | -182,180,000 | -239,556,000 | 556,536,000 | 563,288,000 | — | -182,728,000 |
| Dec 2023 | 15,843,000 | -282,486,000 | -308,478,000 | 831,689,000 | 624,019,000 | — | -145,929,000 |
| Dec 2022 | 106,483,000 | -144,246,000 | -126,789,000 | 704,964,000 | 228,955,000 | — | -145,060,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRON | Disc Medicine, Inc. | $2.93B | $76.59 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $2.94B | $63.44 | — |
| MBX | MBX Biosciences, Inc. | $2.91B | $61.05 | — |
| VERA | Vera Therapeutics, Inc. | $3.01B | $42.00 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.81B | $48.46 | — |
News headlines (Yahoo Finance, 1h cache)
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
2026-07-01 13:55 · Yahoo
XBI Ignored The Market's Downturn
2026-06-29 23:53 · Yahoo
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
2026-06-25 20:10 · Yahoo
UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances
2026-06-25 12:41 · Yahoo
uniQure Announces Pricing of Upsized $225 Million Public Offering
2026-06-24 01:13 · Yahoo
uniQure Announces $150 Million Proposed Public Offering
2026-06-22 20:01 · Yahoo
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
2026-06-22 14:29 · Yahoo
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
2026-06-19 18:19 · Yahoo
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
2026-06-19 12:24 · Yahoo
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
2026-06-19 11:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.